179 related articles for article (PubMed ID: 31308062)
21. First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors.
Forero A; Bendell JC; Kumar P; Janisch L; Rosen M; Wang Q; Copigneaux C; Desai M; Senaldi G; Maitland ML
Invest New Drugs; 2017 Jun; 35(3):298-306. PubMed ID: 28050790
[TBL] [Abstract][Full Text] [Related]
22. Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies.
Kitano S; Shimizu T; Koyama T; Ebata T; Iwasa S; Kondo S; Shimomura A; Fujiwara Y; Yamamoto N; Paccaly A; Li S; Rietschel P; Sims T
Cancer Chemother Pharmacol; 2021 Jan; 87(1):53-64. PubMed ID: 33146741
[TBL] [Abstract][Full Text] [Related]
23. Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer.
Blagden SP; Hamilton AL; Mileshkin L; Wong S; Michael A; Hall M; Goh JC; Lisyanskaya AS; DeSilvio M; Frangou E; Stronach EA; Gopalakrishna P; Meniawy TM; Gabra H
Clin Cancer Res; 2019 Mar; 25(5):1472-1478. PubMed ID: 30563934
[TBL] [Abstract][Full Text] [Related]
24. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.
Frenel JS; Le Tourneau C; O'Neil B; Ott PA; Piha-Paul SA; Gomez-Roca C; van Brummelen EMJ; Rugo HS; Thomas S; Saraf S; Rangwala R; Varga A
J Clin Oncol; 2017 Dec; 35(36):4035-4041. PubMed ID: 29095678
[TBL] [Abstract][Full Text] [Related]
25. Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.
Diamond JR; Goff B; Forster MD; Bendell JC; Britten CD; Gordon MS; Gabra H; Waterhouse DM; Poole M; Ross Camidge D; Hamilton E; Moore KM
Invest New Drugs; 2017 Oct; 35(5):627-633. PubMed ID: 28283779
[TBL] [Abstract][Full Text] [Related]
26. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Wouters MC; Kenter GG; van Erkel AR; van Poelgeest MI; Nijman HW; van der Hoeven JJ; Welters MJ; van der Burg SH; Kroep JR
Ann Oncol; 2015 Oct; 26(10):2141-9. PubMed ID: 26216383
[TBL] [Abstract][Full Text] [Related]
27. First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies.
Papadopoulos KP; Johnson ML; Lockhart AC; Moore K; Falchook GS; Formenti SC; Naing A; Carvajal RD; Rosen LS; Weiss GJ; Leidner RS; Li J; Paccaly A; Feng M; Stankevich E; Lowy I; Fury MG; Crittenden MR
Clin Cancer Res; 2020 Mar; 26(5):1025-1033. PubMed ID: 31796520
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.
Shah MH; Lorigan P; O'Brien ME; Fossella FV; Moore KN; Bhatia S; Kirby M; Woll PJ
Invest New Drugs; 2016 Jun; 34(3):290-9. PubMed ID: 26961907
[TBL] [Abstract][Full Text] [Related]
29. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
de Bono JS; Concin N; Hong DS; Thistlethwaite FC; Machiels JP; Arkenau HT; Plummer R; Jones RH; Nielsen D; Windfeld K; Ghatta S; Slomovitz BM; Spicer JF; Yachnin J; Ang JE; Mau-Sørensen PM; Forster MD; Collins D; Dean E; Rangwala RA; Lassen U
Lancet Oncol; 2019 Mar; 20(3):383-393. PubMed ID: 30745090
[TBL] [Abstract][Full Text] [Related]
30. Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.
Piha-Paul SA; Wheler JJ; Fu S; Levenback C; Lu K; Falchook GS; Naing A; Hong DS; Tsimberidou AM; Kurzrock R
Oncotarget; 2014 Apr; 5(7):1846-55. PubMed ID: 24742900
[TBL] [Abstract][Full Text] [Related]
31. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
[TBL] [Abstract][Full Text] [Related]
32. A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer.
Forster M; Kaye S; Oza A; Sklenar I; Johri A; Cheung W; Zaknoen S; Gore M
Clin Cancer Res; 2007 Jul; 13(14):4178-84. PubMed ID: 17634546
[TBL] [Abstract][Full Text] [Related]
33. An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
Parma G; Mancari R; Del Conte G; Scambia G; Gadducci A; Hess D; Katsaros D; Sessa C; Rinaldi A; Bertoni F; Vitali A; Catapano CV; Marsoni S; van de Velde H; Colombo N
Int J Gynecol Cancer; 2012 Jun; 22(5):792-800. PubMed ID: 22635029
[TBL] [Abstract][Full Text] [Related]
34. Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
Bahleda R; Grilley-Olson JE; Govindan R; Barlesi F; Greillier L; Perol M; Ray-Coquard I; Strumberg D; Schultheis B; Dy GK; Zalcman G; Weiss GJ; Walter AO; Kornacker M; Rajagopalan P; Henderson D; Nogai H; Ocker M; Soria JC
Br J Cancer; 2017 Jun; 116(12):1505-1512. PubMed ID: 28463960
[TBL] [Abstract][Full Text] [Related]
35. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.
Hansen AR; Massard C; Ott PA; Haas NB; Lopez JS; Ejadi S; Wallmark JM; Keam B; Delord JP; Aggarwal R; Gould M; Yang P; Keefe SM; Piha-Paul SA
Ann Oncol; 2018 Aug; 29(8):1807-1813. PubMed ID: 29992241
[TBL] [Abstract][Full Text] [Related]
36. PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer.
Rischin D; Gil-Martin M; González-Martin A; Braña I; Hou JY; Cho D; Falchook GS; Formenti S; Jabbour S; Moore K; Naing A; Papadopoulos KP; Baranda J; Fury W; Feng M; Stankevich E; Li J; Yama-Dang NA; Yoo SY; Lowy I; Mathias M; Fury MG
Gynecol Oncol; 2020 Nov; 159(2):322-328. PubMed ID: 32917410
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study.
Secord AA; Blessing JA; Armstrong DK; Rodgers WH; Miner Z; Barnes MN; Lewandowski G; Mannel RS;
Gynecol Oncol; 2008 Mar; 108(3):493-9. PubMed ID: 18191993
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix.
Irvin WP; Price FV; Bailey H; Gelder M; Rosenbluth R; Durivage HJ; Potkul RK
Cancer; 1998 Jan; 82(2):328-33. PubMed ID: 9445190
[TBL] [Abstract][Full Text] [Related]
39. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.
Shen L; Guo J; Zhang Q; Pan H; Yuan Y; Bai Y; Liu T; Zhou Q; Zhao J; Shu Y; Huang X; Wang S; Wang J; Zhou A; Ye D; Sun T; Gao Y; Yang S; Wang Z; Li J; Wu YL
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561638
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients.
Chambers SK; Davis CA; Chambers JT; Schwartz PE; Lorber MI; Hschumacher RE
Clin Cancer Res; 1996 Oct; 2(10):1699-704. PubMed ID: 9816119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
